Aligos TherapeuticsALGS -2.22%37 PB Ratio is 1.29 as of Jul. 11, 2026, which is 111% above its 10-year median of 0.61. GuruFocus rates ALGS with a GF Score™ of 37/100 and a GF Value™ of $2.78 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,227 Biotechnology companies, Aligos Therapeutics ranks better than 75.63% on this metric.
The historical rank and industry rank for Aligos Therapeutics's PB Ratio or its related term are showing as below:
ALGS'
s PB Ratio Range Over the Past 10 Years
Min: 0.21 Med: 0.61 Max: 6.57
Current: 1.29
During the past 8 years, Aligos Therapeutics's highest PB Ratio was 6.57. The lowest was 0.21. And the median was 0.61.
ALGS's PB Ratio is ranked better than 75.63% of 1227
companies
in the Biotechnology industry
Industry Median: 2.95
vs ALGS: 1.29
During the past 12 months, Aligos Therapeutics's average Book Value Per Share Growth Rate was -73.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -47.70% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Aligos Therapeutics was -41.10% per year. The lowest was -47.70% per year. And the median was -44.40% per year.
Back to Basics: PB Ratio
Aligos Therapeutics (NAS:ALGS) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Aligos Therapeutics PB Ratio Related Terms
Aligos Therapeutics PB Ratio Historical Data
* Premium members only.
The historical data trend for Aligos Therapeutics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Aligos Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aligos Therapeutics PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aligos Therapeutics's PB Ratio distribution charts can be found below:
* The bar in red indicates where Aligos Therapeutics's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Aligos Therapeutics (ALGS) has a PB Ratio of 1.29 as of Jul. 11, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aligos Therapeutics and its competitors. This is 111% above median its historical median of 0.61. Over the past decade, Aligos Therapeutics' PB Ratio has ranged from 0.21 to 6.57. According to the industry distribution chart, Aligos Therapeutics ranks #299 out of 1227 companies in the Biotechnology industry, placing it in the top 24.4%.
Is Aligos Therapeutics' PB Ratio too high?
Aligos Therapeutics' current PB Ratio of 1.29 is 111% above median its 10-year median of 0.61. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 6.57. The Biotechnology industry median PB Ratio is 2.95. Aligos Therapeutics' value of 1.29 is 56.3% below this industry median. Based on the distribution chart, Aligos Therapeutics ranks #299 out of 1227 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Aligos Therapeutics has a GF Score™ of 37/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aligos Therapeutics' PB Ratio compare to SNTI and NTRB?
According to the Biotechnology industry distribution chart, Aligos Therapeutics ranks #299 out of 1227 companies for PB Ratio. This places Aligos Therapeutics in the top 24% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.95. Aligos Therapeutics' value of 1.29 is 56.3% below this benchmark. Historically, Aligos Therapeutics' own PB Ratio has ranged from 0.21 to 6.57 over the past decade. While the company's 10-year median is 0.61 vs. the industry median of 2.95, Aligos Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.95, based on 1,227 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aligos Therapeutics's current PB Ratio of 1.29 is 56.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Aligos Therapeutics and its competitors. For the Biotechnology industry, the median PB Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aligos Therapeutics's current PB Ratio is 1.29, which is 111% above median its own 10-year median of 0.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aligos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Aligos Therapeutics (ALGS) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.78, compared to a current price of $6.63 — trading 138.5% above its estimated fair value. The current PB Ratio is 1.29, which is 111% above median its 10-year median of 0.61 and 56.3% below the Biotechnology industry median of 2.95. Aligos Therapeutics' overall GF Score™ is 37/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Aligos Therapeutics (ALGS), the current PB Ratio is 1.29 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aligos Therapeutics (ALGS) Overvalued in 2026?
Based on GuruFocus' analysis, Aligos Therapeutics stock appears to be overvalued.
The current stock price of $6.63 is trading 138.5% above its estimated GF Value™ of $2.78.
GuruFocus considers Aligos Therapeutics to be Significantly Overvalued.
Key valuation signals for ALGS:
PB Ratio: 1.29 (111% above median its 10-year median of 0.61)
GF Value™: $2.78 vs. price of $6.63 (138.5% above fair value)
Industry Position: 56.3% below the Biotechnology median (#299 of 1227)
No single metric tells the full story. See the ALGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
37GF Score
Get the complete analysis for ALGS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ALGS has been successfully added to your 
